Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Pech T et al. | Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats. | 2012 | Transplantation | pmid:22167049 |
Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
Sheiner PA et al. | Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. | 1997 | Transplantation | pmid:9355846 |
Reding R et al. | Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. | 1994 | Transplantation | pmid:7507272 |
Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
Cassuto E et al. | Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study. | 2016 | Transplantation | pmid:27653227 |
Jurcevic S et al. | A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. | 1998 | Transplantation | pmid:9603168 |
Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
Augustine JJ et al. | Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. | 2006 | Transplantation | pmid:16612276 |
Tan HP et al. | Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. | 2008 | Transplantation | pmid:19104412 |
Curran CF et al. | Acute overdoses of tacrolimus. | 1996 | Transplantation | pmid:8932293 |
Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
van Hooff JP et al. | Tacrolimus and posttransplant diabetes mellitus in renal transplantation. | 2005 | Transplantation | pmid:15940032 |
Gaber AO et al. | Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. | 2013 | Transplantation | pmid:23715050 |
Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |
Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |